Immunocore Holdings plc (IMCR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$452.7M
Cash & Equivalents
$13.8M
Quarterly Burn Rate
99 mo
Est. Cash Runway
$1,624M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase2 Readout | — |
| 2026-11-30 | Phase2 Readout | — |
| 2026-12-30 | Phase2 Readout | — |
Active Clinical Trials (10)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | PHASE3 | Recruiting | 540 |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma | PHASE3 | Recruiting | 290 |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | PHASE3 | Recruiting | 680 |
| NCT06627244 | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | PHASE2 | Recruiting | 30 |
| NCT06414590 | Neoadjuvant Tebentafusp for Uveal Melanoma | PHASE2 | Recruiting | 19 |
| NCT06070012 | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | PHASE2 | Recruiting | 44 |
| NCT06840119 | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | PHASE2 | Recruiting | 600 |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | PHASE2 | Active Not Recruiting | 410 |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma | PHASE2 | Active Not Recruiting | 850 |
| NCT07156136 | Study of IMC-P115C in Advanced PRAME-Positive Cancers | PHASE1 | Recruiting | 140 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.